On June 27, 2023 A voluntary partial clinical hold has been reported on a trial in which Starpharma (ASX: SPL, OTCQX: SPHRY) technology is used: AZD0466 Monotherapy or in Combination in Patients with Advanced Haematological Malignancies (NCT04865419) (Press release, Starpharma, JUN 27, 2023, View Source;mc_eid=bf52dd3418 [SID1234632910]). This Phase 1/2 study is in the dose escalation phase.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The asymptomatic reported events leading to the voluntary partial hold were assessed as not related to Starpharma’s DEP dendrimer. The voluntary partial clinical hold does not impact
Starpharma’s platform technology, or other clinical DEP programs or partnerships.

The other clinical study of AZD0466 in patients with non-Hodgkin’s lymphoma (NCT05205161) is not impacted and continues to enroll patients.

Starpharma will provide further details to the market when additional relevant information becomes available. AstraZeneca (LSE/STO/Nasdaq: AZN) is the study sponsor.